$SIONSionna Therapeutics, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Epic's AI push overlaps with health tech startups
  VERONA, WI — Epic showed off its continued expansion of AI for clinicians and patients at its annual Users Group Meeting on Tuesday, putting pressure on startups across the health tech industry. Dr…
  endpoints · 16h ago
• FDA pick Heidi Overton has been critical of vaccine requirements, abortion pills
  The FDA's next chapter is officially underway. President Donald Trump announced Heidi Overton as his pick for FDA commissioner in a social media post Wednesday. Numerous outlets, including Endpoint…
  endpoints · 1d ago
• Trump to pick Heidi Overton to lead the FDA
  President Donald Trump is expected to nominate Heidi Overton to be the next FDA commissioner, according to a source familiar with the decision, setting a new chapter for the drug agency three ...
  endpoints · 2d ago
• Epic is under pressure
  I spent Monday night in downtown Madison, WI, snacking on cheese curds and chatting with folks at happy hours ahead of the keynote session at Epic’s annual meeting for customers this morning. Epic…
  endpoints · 2d ago
• 'Incorrect and misleading' data prompted decision to pull Tavneos in Europe
  European regulators on Thursday explained last week's decision to pull Amgen's rare disease drug Tavneos from the market there, detailing their skepticism about the data. In new documents posted Th…
  endpoints · 7d ago
• Karyopharm has a month left to salvage its cancer expansion plans
  A commercial-stage cancer drugmaker with a market cap about one-third the size of its projected 2026 revenues is on the brink of defaulting. Karyopharm Therapeutics said Thursday that it has until ...
  endpoints · 7d ago
• Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
  Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
  biopharma_dive · 10d ago
• Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex
  Sionna Therapeutics’ bid to become the next cystic fibrosis drug developer after Vertex Pharmaceuticals has taken a major hit, after Sionna reported that its lead asset failed an early study and ...
  endpoints · 10d ago
• Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
  A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
  biospace · 10d ago
• STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
  A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.
  stat · 10d ago